The study utilized the APP/PS1 mouse model of AD, which exhibits strong pathophysiologies, including Aβ1–42 deposition, impaired tau protein levels (an indicator of AD progression), and reduced cognitive function. This evidence concerns the gene APP and Alzheimer disease.